Through a glass, darkly? HepaRG and HepG2 cells as models of human phase I drug metabolism

References

• Aninat C, Piton A, Glaise D, Le Charpentier T, Langouët S, Morel F, Guguen-Guillouzo C, Guillouzo A. 2006. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos. 34(1):75–83.
   PubMed Web of Science ®Google Scholar
• Anthérieu S, Chesné C, Li R, Camus S, Lahoz A, Picazo L, Turpeinen M, Tolonen A, Uusitalo J, Guguen-Guillouzo C, et al. 2010. Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells. Drug Metab Dispos. 38(3):516–525.
   PubMed Web of Science ®Google Scholar
• Berger B, Donzelli M, Maseneni S, Boess F, Roth A, Krähenbühl S, Haschke M. 2016. Comparison of liver cell models using the basel phenotyping cocktail. Front Pharmacol. 7:443.
   PubMed Web of Science ®Google Scholar
• Berger E, Vega N, Weiss-Gayet M, Géloën A. 2015. Gene network analysis of glucose linked signaling pathways and their role in human hepatocellular carcinoma cell growth and survival in HuH7 and HepG2 cell lines. Biomed Res Int. 2015:821761.
   PubMed Web of Science ®Google Scholar
• Bernasconi C, Pelkonen O, Andersson TB, Strickland J, Wilk-Zasadna I, Asturiol D, Cole T, Liska R, Worth A, Müller-Vieira U, et al. 2019. Validation of in vitro methods for human cytochrome P450 enzyme induction: outcome of a multi-laboratory study. Toxicol In Vitro. 60:212–228.
   PubMed Web of Science ®Google Scholar
• Bonn B, Svanberg P, Janefeldt A, Hultman I, Grime K. 2016. Determination of human hepatocyte intrinsic clearance for slowly metabolized compounds: comparison of a primary hepatocyte/stromal cell co-culture with plated primary hepatocytes and HepaRG. Drug Metab Dispos. 44(4):527–533.
   PubMed Web of Science ®Google Scholar
• Buccitelli C, Selbach M. 2020. mRNAs, proteins and the emerging principles of gene expression control. Nat Rev Genet. 21(10):630–644.
   PubMed Web of Science ®Google Scholar
• Chen L, Bao Y, Piekos SC, Zhu K, Zhang L, Zhong XB. 2018. A transcriptional regulatory network containing nuclear receptors and long noncoding RNAs controls basal and drug-induced expression of cytochrome P450s in HepaRG cells. Mol Pharmacol. 94(1):749–759.
   PubMed Web of Science ®Google Scholar
• Choi JM, Oh SJ, Lee JY, Jeon JS, Ryu CS, Kim YM, Lee K, Kim SK. 2015. Prediction of drug-induced liver injury in HepG2 cells cultured with human liver microsomes. Chem Res Toxicol. 28(5):872–885.
   PubMed Web of Science ®Google Scholar
• Chu V, Einolf HJ, Evers R, Kumar G, Moore D, Ripp S, Silva J, Sinha V, Sinz M, Skerjanec A. 2009. In vitro and in vivo induction of cytochrome P450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of America perspective. Drug Metab Dispos. 37(7):1339–1354.
   PubMed Web of Science ®Google Scholar
• Dawson JR, Adams DJ, Wolf CR. 1985. Induction of drug metabolizing enzymes in human liver cell line HepG2. FEBS Lett. 183(2):219–222.
   PubMed Web of Science ®Google Scholar
• Dearfield KL, Jacobson-Kram D, Brown NA, Williams JR. 1983. Evaluation of a human hepatoma cell line as a target cell in genetic toxicology. Mutat Res. 108(1–3):437–449.
   PubMed Web of Science ®Google Scholar
• Easterbrook J, Lu C, Sakai Y, Li AP. 2001. Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab Dispos. 29(2):141–144.
   PubMed Web of Science ®Google Scholar
• El-Sankary W, Plant NJ, Gibson GG, Moore DJ. 2000. Regulation of the CYP3A4 gene by hydrocortisone and xenobiotics: role of the glucocorticoid and pregnane X receptors. Drug Metab Dispos. 28(5):493–496.
   PubMed Web of Science ®Google Scholar
• Gerets HH, Tilmant K, Gerin B, Chanteux H, Depelchin BO, Dhalluin S, Atienzar FA. 2012. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 28(2):69–87.
   PubMed Web of Science ®Google Scholar
• Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, Guguen-Guillouzo C. 2002. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA. 99(24):15655–15660.
   PubMed Web of Science ®Google Scholar
• Hammer H, Schmidt F, Marx-Stoelting P, Pötz O, Braeuning A. 2021. Cross-species analysis of hepatic cytochrome P450 and transport protein expression. Arch Toxicol. 95(1):117–133.
   PubMed Web of Science ®Google Scholar
• Harmsen S, Koster AS, Beijnen JH, Schellens JH, Meijerman I. 2008. Comparison of two immortalized human cell lines to study nuclear receptor-mediated CYP3A4 induction. Drug Metab Dispos. 36(6):1166–1171.
   PubMed Web of Science ®Google Scholar
• Henderson CJ, Kapelyukh Y, Scheer N, Rode A, McLaren AW, MacLeod AK, Lin D, Wright J, Stanley LA, Wolf CR. 2019. An extensively humanized mouse model to predict pathways of drug disposition and drug/drug interactions, and to facilitate design of clinical trials. Drug Metab Dispos. 47(6):601–615.
   PubMed Web of Science ®Google Scholar
• Hurrell T, Segeritz CP, Vallier L, Lilley KS, Cromarty AD. 2018. Proteomic comparison of various hepatic cell cultures for preclinical safety pharmacology. Toxicol Sci. 164(1):229–239.
   PubMed Web of Science ®Google Scholar
• Jackson JP, Li L, Chamberlain ED, Wang H, Ferguson SS. 2016. Contextualizing hepatocyte functionality of cryopreserved HepaRG cell cultures. Drug Metab Dispos. 44(9):1463–1479.
   PubMed Web of Science ®Google Scholar
• Jossé R, Aninat C, Glaise D, Dumont J, Fessard V, Morel F, Poul JM, Guguen-Guillouzo C, Guillouzo A. 2008. Long-term functional stability of human HepaRG hepatocytes and use for chronic toxicity and genotoxicity studies. Drug Metab Dispos. 36(6):1111–1118.
   PubMed Web of Science ®Google Scholar
• Kanebratt KP, Andersson TB. 2008a. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab Dispos. 36(7):1444–1452.
   PubMed Web of Science ®Google Scholar
• Kanebratt KP, Andersson TB. 2008b. HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab Dispos. 36(1):137–145.
   PubMed Web of Science ®Google Scholar
• Kaneko A, Kato M, Sekiguchi N, Mitsui T, Takeda K, Aso Y. 2009. In vitro model for the prediction of clinical CYP3A4 induction using HepaRG cells. Xenobiotica. 39(11):803–810.
   PubMed Web of Science ®Google Scholar
• Kelly JH, Sussman NL. 2000. A fluorescent cell-based assay for cytochrome P-450 isozyme 1A2 induction and inhibition. J Biomol Screen. 5(4):249–254.
   PubMedGoogle Scholar
• Khoo KC, Mendels J, Rothbart M, Garland WA, Colburn WA, Min BH, Lucek R, Carbone JJ, Boxenbaum HG, Kaplan SA. 1980. Influence of phenytoin and phenobarbital on the disposition of a single oral dose of clonazepam. Clin Pharmacol Ther. 28(3):368–375.
   PubMed Web of Science ®Google Scholar
• Knowles BB, Howe CC, Aden DP. 1980. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science. 209(4455):497–499.
   PubMed Web of Science ®Google Scholar
• Koutsounas I, Theocharis S, Patsouris E, Giaginis C. 2013. Pregnane X receptor (PXR) at the crossroads of human metabolism and disease. Curr Drug Metab. 14(3):341–350.
   PubMed Web of Science ®Google Scholar
• Kratochwil NA, Meille C, Fowler S, Klammers F, Ekiciler A, Molitor B, Simon S, Walter I, McGinnis C, Walther J, et al. 2017. Metabolic profiling of human long-term liver models and hepatic clearance predictions from in vitro data using nonlinear mixed-effects modeling. Aaps J. 19(2):534–550.
   PubMed Web of Science ®Google Scholar
• Kvist AJ, Kanebratt KP, Walentinsson A, Palmgren H, O'Hara M, Björkbom A, Andersson LC, Ahlqvist M, Andersson TB. 2018. Critical differences in drug metabolic properties of human hepatic cellular models, including primary human hepatocytes, stem cell derived hepatocytes, and hepatoma cell lines. Biochem Pharmacol. 155:124–140.
   PubMed Web of Science ®Google Scholar
• Lübberstedt M, Müller-Vieira U, Mayer M, Biemel KM, Knöspel F, Knobeloch D, Nüssler AK, Gerlach JC, Zeilinger K. 2011. HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. J Pharmacol Toxicol Methods. 63(1):59–68.
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Zhang G, Kenny JR, Hamilton GA, Otmani S, Stams KR, Haney S, Brassil P, Stresser DM, Riley RJ. 2009. Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells. Drug Metab Dispos. 37(6):1259–1268.
   PubMed Web of Science ®Google Scholar
• McMahon M, Ding S, Jimenez LA, Terranova R, Gerard MA, Vitobello A, Moggs J, Henderson CJ, Wolf CR. 2019. Constitutive androstane receptor 1 is constitutively bound to chromatin and ‘primed’ for transactivation in hepatocytes. Mol Pharmacol. 95(1):97–105.
   PubMed Web of Science ®Google Scholar
• Negishi M, Kobayashi K, Sakuma T, Sueyoshi T. 2020. Nuclear receptor phosphorylation in xenobiotic signal transduction. J Biol Chem. 295(45):15210–15225.
   PubMed Web of Science ®Google Scholar
• Nelson LJ, Morgan K, Treskes P, Samuel K, Henderson CJ, LeBled C, Homer N, Grant MH, Hayes PC, Plevris JN. 2017. Human hepatic HepaRG cells maintain an organotypic phenotype with high intrinsic CYP450 activity/metabolism and significantly outperform standard HepG2/C3A cells for pharmaceutical and therapeutic applications. Basic Clin Pharmacol Toxicol. 120(1):30–37.
   PubMed Web of Science ®Google Scholar
• Nofziger C, Turner AJ, Sangkuhl K, Whirl-Carrillo M, Agúndez JAG, Black JL, Dunnenberger HM, Ruano G, Kennedy MA, Phillips MS, et al. 2020. PharmVar GeneFocus: CYP2D6. Clin Pharmacol Ther. 107(1):154–170.
   PubMed Web of Science ®Google Scholar
• OECD. 2019. Determination of Cytochrome P450 (CYP) enzyme activity induction using differentiated human hepatic cells. [accessed 2021 Aug 2]. https://www.oecd.org/chemicalsafety/testing/Draft_TG_CYP_induction_for_2nd_WNT_review.pdf
   Google Scholar
• Parent R, Marion MJ, Furio L, Trépo C, Petit MA. 2004. Origin and characterization of a human bipotent liver progenitor cell line. Gastroenterology. 126(4):1147–1156.
   PubMed Web of Science ®Google Scholar
• Preiss LC, Liu R, Hewitt P, Thompson D, Georgi K, Badolo L, Lauschke VM, Petersson C. 2021. Deconvolution of cytochrome P450 induction mechanisms in HepaRG nuclear hormone receptor knockout cells. Drug Metab Dispos. 49(8):668–678.
   PubMed Web of Science ®Google Scholar
• Ramaiahgari SC, Waidyanatha S, Dixon D, DeVito MJ, Paules RS, Ferguson SS. 2017. From the cover: three-dimensional (3D) HepaRG spheroid model with physiologically relevant xenobiotic metabolism competence and hepatocyte functionality for liver toxicity screening. Toxicol Sci. 159(1):124–136.
   PubMed Web of Science ®Google Scholar
• Rowe C, Gerrard DT, Jenkins R, Berry A, Durkin K, Sundstrom L, Goldring CE, Park BK, Kitteringham NR, Hanley KP, et al. 2013. Proteome-wide analyses of human hepatocytes during differentiation and dedifferentiation. Hepatology. 58(2):799–809.
   PubMed Web of Science ®Google Scholar
• Sangkuhl K, Claudio-Campos K, Cavallari LH, Agundez JAG, Whirl-Carrillo M, Duconge J, Del Tredici AL, Wadelius M, Rodrigues Botton M, Woodahl EL, et al. 2021. PharmVar GeneFocus: CYP2C9. Clin Pharmacol Ther. 110(3):662–676.
   PubMed Web of Science ®Google Scholar
• Scheer N, Ross J, Rode A, Zevnik B, Niehaves S, Faust N, Wolf CR. 2008. A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response. J Clin Invest. 118(9):3228–3239.
   PubMed Web of Science ®Google Scholar
• Seo JE, Tryndyak V, Wu Q, Dreval K, Pogribny I, Bryant M, Zhou T, Robison TW, Mei N, Guo X. 2019. Quantitative comparison of in vitro genotoxicity between metabolically competent HepaRG cells and HepG2 cells using the high-throughput high-content CometChip assay. Arch Toxicol. 93(5):1433–1448.
   PubMed Web of Science ®Google Scholar
• Seo JE, Wu Q, Bryant M, Ren L, Shi Q, Robison TW, Mei N, Manjanatha MG, Guo X. 2020. Performance of high-throughput CometChip assay using primary human hepatocytes: a comparison of DNA damage responses with in vitro human hepatoma cell lines. Arch Toxicol. 94(6):2207–2224.
   PubMed Web of Science ®Google Scholar
• Shi J, Wang X, Lyu L, Jiang H, Zhu HJ. 2018. Comparison of protein expression between human livers and the hepatic cell lines HepG2, Hep3B, and Huh7 using SWATH and MRM-HR proteomics: Focusing on drug-metabolizing enzymes. Drug Metab Pharmacokinet. 33(2):133–140.
   PubMed Web of Science ®Google Scholar
• Sison-Young RL, Mitsa D, Jenkins RE, Mottram D, Alexandre E, Richert L, Aerts H, Weaver RJ, Jones RP, Johann E, et al. 2015. Comparative proteomic characterization of 4 human liver-derived single cell culture models reveals significant variation in the capacity for drug disposition, bioactivation, and detoxication. Toxicol Sci. 147(2):412–424.
   PubMed Web of Science ®Google Scholar
• Stanley LA, Horsburgh BC, Ross J, Scheer N, Wolf CR. 2006. PXR and CAR: nuclear receptors which play a pivotal role in drug disposition and chemical toxicity. Drug Metab Rev. 38(3):515–597.
   PubMed Web of Science ®Google Scholar
• Tascher G, Burban A, Camus S, Plumel M, Chanon S, Le Guevel R, Shevchenko V, Van Dorsselaer A, Lefai E, Guguen-Guillouzo C, et al. 2019. In-depth proteome analysis highlights HepaRG cells as a versatile cell system surrogate for primary human hepatocytes. Cells. 8(2):192.
   PubMed Web of Science ®Google Scholar
• Thomas M, Bayha C, Vetter S, Hofmann U, Schwarz M, Zanger UM, Braeuning A. 2015. Activating and inhibitory functions of WNT/β-catenin in the induction of cytochromes P450 by nuclear receptors in HepaRG cells. Mol Pharmacol. 87(6):1013–1020.
   PubMed Web of Science ®Google Scholar
• Tolosa L, Gómez-Lechón MJ, López S, Guzmán C, Castell JV, Donato MT, Jover R. 2016. Human upcyte hepatocytes: characterization of the hepatic phenotype and evaluation for acute and long-term hepatotoxicity routine testing. Toxicol Sci. 152(1):214–229.
   PubMed Web of Science ®Google Scholar
• Turpeinen M, Tolonen A, Chesne C, Guillouzo A, Uusitalo J, Pelkonen O. 2009. Functional expression, inhibition and induction of CYP enzymes in HepaRG cells. Toxicol In Vitro. 23(4):748–753.
   PubMed Web of Science ®Google Scholar
• Ulvestad M, Nordell P, Asplund A, Rehnström M, Jacobsson S, Holmgren G, Davidson L, Brolén G, Edsbagge J, Björquist P, et al. 2013. Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells. Biochem Pharmacol. 86(5):691–702.
   PubMed Web of Science ®Google Scholar
• van der Mark VA, Rudi de Waart D, Shevchenko V, Elferink RP, Chamuleau RA, Hoekstra R. 2017. Stable overexpression of the constitutive androstane receptor reduces the requirement for culture with dimethyl sulfoxide for high drug metabolism in HepaRG cells. Drug Metab Dispos. 45(1):56–67.
   PubMed Web of Science ®Google Scholar
• Vermet H, Raoust N, Ngo R, Esserméant L, Klieber S, Fabre G, Boulenc X. 2016. Evaluation of normalization methods to predict CYP3A4 induction in six fully characterized cryopreserved human hepatocyte preparations and HepaRG cells. Drug Metab Dispos. 44(1):50–60.
   PubMed Web of Science ®Google Scholar
• Wang Z, Luo X, Anene-Nzelu C, Yu Y, Hong X, Singh NH, Xia L, Liu S, Yu H. 2015. HepaRG culture in tethered spheroids as an in vitro three-dimensional model for drug safety screening. J Appl Toxicol. 35(8):909–917.
   PubMed Web of Science ®Google Scholar
• Wang ZY, Li WJ, Li QG, Jing HS, Yuan TJ, Fu GB, Tang D, Zhang HD, Yan HX, Zhai B. 2019. A DMSO-free hepatocyte maturation medium accelerates hepatic differentiation of HepaRG cells in vitro. Biomed Pharmacother. 116:109010.
   PubMed Web of Science ®Google Scholar
• Weaver RJ, Betts C, Blomme EAG, Gerets HHJ, Gjervig Jensen K, Hewitt PG, Juhila S, Labbe G, Liguori MJ, Mesens N, et al. 2017. Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury. Expert Opin Drug Metab Toxicol. 13(7):767–782.
   PubMed Web of Science ®Google Scholar
• Weaver RJ, Blomme EA, Chadwick AE, Copple IM, Gerets HHJ, Goldring CE, Guillouzo A, Hewitt PG, Ingelman-Sundberg M, Jensen KG, et al. 2020. Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. Nat Rev Drug Discov. 19(2):131–148.
   PubMed Web of Science ®Google Scholar
• Williamson B, Lorbeer M, Mitchell MD, Brayman TG, Riley RJ. 2016. Evaluation of a novel PXR-knockout in HepaRG™ cells. Pharmacol Res Perspect. 4(5):e00264.
   PubMedGoogle Scholar
• Wiśniewski JR, Vildhede A, Norén A, Artursson P. 2016. In-depth quantitative analysis and comparison of the human hepatocyte and hepatoma cell line HepG2 proteomes. J Proteomics. 136:234–247.
   PubMed Web of Science ®Google Scholar
• Wong N, Lai P, Pang E, Leung TW, Lau JW, Johnson PJ. 2000. A comprehensive karyotypic study on human hepatocellular carcinoma by spectral karyotyping. Hepatology. 32(5):1060–1068.
   PubMed Web of Science ®Google Scholar
• Xie Y, Ke S, Chen J, Ouyang N, Tian Y. 2020. Epigenetic sensitization of pregnane X receptor-regulated gene expression by dimethyl sulfoxide. Toxicol Lett. 321:131–137.
   PubMed Web of Science ®Google Scholar
• Yokoyama Y, Sasaki Y, Terasaki N, Kawataki T, Takekawa K, Iwase Y, Shimizu T, Sanoh S, Ohta S. 2018. Comparison of drug metabolism and its related hepatotoxic effects in HepaRG, cryopreserved human hepatocytes, and HepG2 cell cultures. Biol Pharm Bull. 41(5):722–732.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M. 2013. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 138(1):103–141.
   PubMed Web of Science ®Google Scholar
• Zhou B, Ho SS, Greer SU, Spies N, Bell JM, Zhang X, Zhu X, Arthur JG, Byeon S, Pattni R, et al. 2019. Haplotype-resolved and integrated genome analysis of the cancer cell line HepG2. Nucleic Acids Res. 47(8):3846–3861.
   PubMed Web of Science ®Google Scholar